{"transactions":[{"id":4623829,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":37762,"kind":"person","name":"Young Wendy B.","position":1,"cik":"0002042847","reported_name":"Young Wendy B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-21T23:25:34.000Z","date":"2026-09-17","kind":"grant","planned":false,"acquired":true,"shares":25666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On June 11, 2026, the Issuer's board of directors approved the option grant issued to the Reporting Person on June 12, 2026, which grant was subject to stockholder approval of an amendment to the Issuer's 2017 Equity Incentive Plan to increase the number of shares authorized for issuance thereunder. The Issuer's stockholders approved the plan amendment on September 17, 2026 (\"Stockholder Approval Date\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 11, 2026, the Issuer's board of directors approved the option grant issued to the Reporting Person on June 12, 2026, which grant was subject to stockholder approval of an amendment to the Issuer's 2017 Equity Incentive Plan to increase the number of shares authorized for issuance thereunder. The Issuer's stockholders approved the plan amendment on September 17, 2026 (\"Stockholder Approval Date\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"2,138 shares subject to the stock option vested on the Stockholder Approval Date and the remaining 23,528 shares subject to the stock option shall vest in substantially equal installments over a 33-month period, beginning on October 12, 2026."}],"balance_after":25666,"derivative":{"exercise_price":2.98,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":25666},"source":{"system":"sec-edgar","filing":"0001213900-26-101883","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042847/000121390026101883/ownership.xml","form_type":"4"}},{"id":707880,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":30038,"kind":"organization","name":"Coastlands Capital LP","position":1,"cik":"0002068530","reported_name":"Coastlands Capital LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-16T21:08:32.000Z","date":"2026-07-16","kind":"purchase","planned":false,"acquired":true,"shares":1233,"price":2.75,"value":3390.75,"ownership":{"direct":false,"nature":"By Coastlands Capital LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Coastlands Capital LP (\"Coastlands\") and Coastlands Capital GP LLC (the \"General Partner\") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the \"Partnership\"). Coastlands Capital LLC (\"Coastlands GP\") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein."}],"balance_after":388308,"source":{"system":"sec-edgar","filing":"0001104659-26-084300","document":"tm2620655-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000110465926084300/tm2620655-1_4seq1.xml","form_type":"4"}},{"id":707879,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":30038,"kind":"organization","name":"Coastlands Capital LP","position":1,"cik":"0002068530","reported_name":"Coastlands Capital LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-16T21:08:32.000Z","date":"2026-07-14","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":2.65,"value":5300.0,"ownership":{"direct":false,"nature":"By Coastlands Capital LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Coastlands Capital LP (\"Coastlands\") and Coastlands Capital GP LLC (the \"General Partner\") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the \"Partnership\"). Coastlands Capital LLC (\"Coastlands GP\") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein."}],"balance_after":387075,"source":{"system":"sec-edgar","filing":"0001104659-26-084300","document":"tm2620655-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000110465926084300/tm2620655-1_4seq1.xml","form_type":"4"}},{"id":710502,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":30038,"kind":"organization","name":"Coastlands Capital LP","position":1,"cik":"0002068530","reported_name":"Coastlands Capital LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-13T14:30:34.000Z","date":"2026-07-10","kind":"purchase","planned":false,"acquired":true,"shares":1700,"price":2.7,"value":4590.0,"ownership":{"direct":false,"nature":"By Coastlands Capital LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Coastlands Capital LP (\"Coastlands\") and Coastlands Capital GP LLC (the \"General Partner\") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the \"Partnership\"). Coastlands Capital LLC (\"Coastlands GP\") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein."}],"balance_after":385075,"source":{"system":"sec-edgar","filing":"0001104659-26-082972","document":"tm2620210-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000110465926082972/tm2620210-1_4seq1.xml","form_type":"4"}},{"id":710501,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":30038,"kind":"organization","name":"Coastlands Capital LP","position":1,"cik":"0002068530","reported_name":"Coastlands Capital LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-13T14:30:34.000Z","date":"2026-07-09","kind":"purchase","planned":false,"acquired":true,"shares":10053,"price":2.79,"value":28047.87,"ownership":{"direct":false,"nature":"By Coastlands Capital LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Coastlands Capital LP (\"Coastlands\") and Coastlands Capital GP LLC (the \"General Partner\") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the \"Partnership\"). Coastlands Capital LLC (\"Coastlands GP\") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein."}],"balance_after":383375,"source":{"system":"sec-edgar","filing":"0001104659-26-082972","document":"tm2620210-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000110465926082972/tm2620210-1_4seq1.xml","form_type":"4"}},{"id":720770,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":30038,"kind":"organization","name":"Coastlands Capital LP","position":1,"cik":"0002068530","reported_name":"Coastlands Capital LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-01T14:30:13.000Z","date":"2026-06-29","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":2.6,"value":65000.0,"ownership":{"direct":false,"nature":"By Coastlands Capital LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Coastlands Capital LP (\"Coastlands\") and Coastlands Capital GP LLC (the \"General Partner\") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the \"Partnership\"). Coastlands Capital LLC (\"Coastlands GP\") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein."}],"balance_after":373322,"source":{"system":"sec-edgar","filing":"0001104659-26-079686","document":"tm2619520-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000110465926079686/tm2619520-1_4seq1.xml","form_type":"4"}},{"id":735899,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":37606,"kind":"person","name":"Davidson Matt","position":1,"cik":"0001741937","reported_name":"Davidson Matt","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-16T10:36:48.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":232417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026."}],"balance_after":232417,"derivative":{"exercise_price":2.89,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":232417},"source":{"system":"sec-edgar","filing":"0001213900-26-069037","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026069037/ownership.xml","form_type":"4"}},{"id":735898,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":37606,"kind":"person","name":"Davidson Matt","position":1,"cik":"0001741937","reported_name":"Davidson Matt","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Series A Preferred Stock","published_at":"2026-06-16T10:36:48.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":101.298,"ownership":{"direct":false,"nature":"By Matt and Alli Davidson Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the \"Merger\"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock (\"Series A Preferred Stock\") in accordance with the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the \"Merger\"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock (\"Series A Preferred Stock\") in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust."}],"balance_after":1923.428,"source":{"system":"sec-edgar","filing":"0001213900-26-069037","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026069037/ownership.xml","form_type":"4"}},{"id":735897,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":37606,"kind":"person","name":"Davidson Matt","position":1,"cik":"0001741937","reported_name":"Davidson Matt","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Series A Preferred Stock","published_at":"2026-06-16T10:36:48.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":1822.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. (\"Azora\"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 (\"Merger Agreement\"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), and Azora."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the \"Merger\"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock (\"Series A Preferred Stock\") in accordance with the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. (\"Azora\"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 (\"Merger Agreement\"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), and Azora."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the \"Merger\"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock (\"Series A Preferred Stock\") in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock."}],"balance_after":1822.13,"source":{"system":"sec-edgar","filing":"0001213900-26-069037","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026069037/ownership.xml","form_type":"4"}},{"id":735896,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":37606,"kind":"person","name":"Davidson Matt","position":1,"cik":"0001741937","reported_name":"Davidson Matt","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-06-16T10:36:48.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":232417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents an award of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026."}],"balance_after":297491,"source":{"system":"sec-edgar","filing":"0001213900-26-069037","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026069037/ownership.xml","form_type":"4"}},{"id":735895,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":37606,"kind":"person","name":"Davidson Matt","position":1,"cik":"0001741937","reported_name":"Davidson Matt","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-06-16T10:36:48.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":3427,"ownership":{"direct":false,"nature":"By Matt and Alli Davidson Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the \"Merger\"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock (\"Series A Preferred Stock\") in accordance with the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement."},{"field":"shares","element":"transactionShares","label":"F3","text":"Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the \"Merger\"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock (\"Series A Preferred Stock\") in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust."}],"balance_after":3427,"source":{"system":"sec-edgar","filing":"0001213900-26-069037","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026069037/ownership.xml","form_type":"4"}},{"id":735894,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":37606,"kind":"person","name":"Davidson Matt","position":1,"cik":"0001741937","reported_name":"Davidson Matt","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-06-16T10:36:48.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":61647,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. (\"Azora\"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 (\"Merger Agreement\"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), and Azora."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the \"Merger\"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock (\"Series A Preferred Stock\") in accordance with the Merger Agreement."},{"field":"shares","element":"transactionShares","label":"F1","text":"Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. (\"Azora\"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 (\"Merger Agreement\"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), and Azora."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. (\"Azora\"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 (\"Merger Agreement\"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), and Azora."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the \"Merger\"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock (\"Series A Preferred Stock\") in accordance with the Merger Agreement."}],"balance_after":61647,"source":{"system":"sec-edgar","filing":"0001213900-26-069037","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026069037/ownership.xml","form_type":"4"}},{"id":736492,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":37762,"kind":"person","name":"Young Wendy B.","position":1,"cik":"0002042847","reported_name":"Young Wendy B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-funded Warrant","published_at":"2026-06-16T10:14:30.000Z","date":"2026-06-12","kind":"purchase","planned":false,"acquired":true,"shares":36378,"price":2.7489,"value":99999.4842,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Pre-Funded Warrant to Purchase Common Stock, dated June 12, 2026, issued by the Issuer to the Reporting Person pursuant to a securities purchase agreement entered into by and among the Issuer, the Reporting Person and certain other parties on June 11, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The pre-funded warrants to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") have no expiration date and are exercisable at any time after receiving approval of the Issuer's stockholders. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The pre-funded warrants to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") have no expiration date and are exercisable at any time after receiving approval of the Issuer's stockholders. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."}],"balance_after":36378,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":36378},"source":{"system":"sec-edgar","filing":"0001213900-26-069021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042847/000121390026069021/ownership.xml","form_type":"4"}},{"id":811503,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53084,"kind":"person","name":"Goodman Tony","position":1,"cik":"0001717971","reported_name":"Goodman Tony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-04-09T21:00:10.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":26510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":26523,"source":{"system":"sec-edgar","filing":"0001213900-26-042054","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1717971/000121390026042054/ownership.xml","form_type":"4"}},{"id":811295,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53055,"kind":"person","name":"Anderson J. Kermit","position":1,"cik":"0001717983","reported_name":"Anderson J. Kermit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-09T21:00:09.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":9185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":9185,"derivative":{"exercise_price":1.64,"expiration_date":"2036-04-06","underlying":"Common Stock","underlying_shares":9185},"source":{"system":"sec-edgar","filing":"0001213900-26-042055","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026042055/ownership.xml","form_type":"4"}},{"id":811294,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:00:07.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":9185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":9213,"source":{"system":"sec-edgar","filing":"0001213900-26-042052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026042052/ownership.xml","form_type":"4"}},{"id":811508,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53085,"kind":"person","name":"Shah Vinay","position":1,"cik":"0001753078","reported_name":"Shah Vinay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-09T21:00:06.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":17325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":17325,"source":{"system":"sec-edgar","filing":"0001213900-26-042053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1753078/000121390026042053/ownership.xml","form_type":"4"}},{"id":811293,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53053,"kind":"person","name":"Gilliland Robertson H.","position":1,"cik":"0001718351","reported_name":"Gilliland Robertson H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:00:04.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":9185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":9185,"source":{"system":"sec-edgar","filing":"0001213900-26-042051","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026042051/ownership.xml","form_type":"4"}},{"id":811331,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53062,"kind":"person","name":"Claiborne Cary J","position":1,"cik":"0001370930","reported_name":"Claiborne Cary J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-09T21:00:03.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":37985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":40417,"source":{"system":"sec-edgar","filing":"0001213900-26-042050","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370930/000121390026042050/ownership.xml","form_type":"4"}},{"id":1127277,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53053,"kind":"person","name":"Gilliland Robertson H.","position":1,"cik":"0001718351","reported_name":"Gilliland Robertson H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:01:36.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025."}],"balance_after":28000,"derivative":{"exercise_price":0.688,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001213900-25-050021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025050021/ownership.xml","form_type":"4"}},{"id":1127276,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":78988,"kind":"person","name":"Newman James W. Jr.","position":1,"cik":"0001718364","reported_name":"Newman James W. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:01:35.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025."}],"balance_after":28000,"derivative":{"exercise_price":0.688,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001213900-25-050020","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025050020/ownership.xml","form_type":"4"}},{"id":1127733,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53085,"kind":"person","name":"Shah Vinay","position":1,"cik":"0001753078","reported_name":"Shah Vinay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:01:34.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025."}],"balance_after":9000,"derivative":{"exercise_price":0.688,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001213900-25-050019","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1753078/000121390025050019/ownership.xml","form_type":"4"}},{"id":1127275,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:01:32.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025."}],"balance_after":28000,"derivative":{"exercise_price":0.688,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001213900-25-050018","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025050018/ownership.xml","form_type":"4"}},{"id":1127312,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53062,"kind":"person","name":"Claiborne Cary J","position":1,"cik":"0001370930","reported_name":"Claiborne Cary J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:01:31.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":138000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025."}],"balance_after":138000,"derivative":{"exercise_price":0.688,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":138000},"source":{"system":"sec-edgar","filing":"0001213900-25-050017","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370930/000121390025050017/ownership.xml","form_type":"4"}},{"id":1127716,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53084,"kind":"person","name":"Goodman Tony","position":1,"cik":"0001717971","reported_name":"Goodman Tony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:01:30.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":94000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025."}],"balance_after":94000,"derivative":{"exercise_price":0.688,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":94000},"source":{"system":"sec-edgar","filing":"0001213900-25-050016","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1717971/000121390025050016/ownership.xml","form_type":"4"}},{"id":1127274,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53055,"kind":"person","name":"Anderson J. Kermit","position":1,"cik":"0001717983","reported_name":"Anderson J. Kermit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:01:29.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025."}],"balance_after":28000,"derivative":{"exercise_price":0.688,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001213900-25-050015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025050015/ownership.xml","form_type":"4"}},{"id":1341400,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53062,"kind":"person","name":"Claiborne Cary J","position":1,"cik":"0001370930","reported_name":"Claiborne Cary J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-05T22:47:13.000Z","date":"2024-12-05","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing December 5, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing December 5, 2024."}],"balance_after":350000,"derivative":{"exercise_price":1.15,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001213900-24-106119","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370930/000121390024106119/ownership.xml","form_type":"4"}},{"id":1361827,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53085,"kind":"person","name":"Shah Vinay","position":1,"cik":"0001753078","reported_name":"Shah Vinay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2024-11-18T21:01:06.000Z","date":"2024-11-16","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."}],"balance_after":40000,"derivative":{"exercise_price":1.06,"exercise_date":"2024-11-16","expiration_date":"2034-11-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-24-099632","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1753078/000121390024099632/ownership.xml","form_type":"4"}},{"id":1559272,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53053,"kind":"person","name":"Gilliland Robertson H.","position":1,"cik":"0001718351","reported_name":"Gilliland Robertson H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T22:21:57.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024."}],"balance_after":12000,"derivative":{"exercise_price":1.35,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001213900-24-026725","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390024026725/ownership.xml","form_type":"4"}},{"id":1559271,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":78988,"kind":"person","name":"Newman James W. Jr.","position":1,"cik":"0001718364","reported_name":"Newman James W. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T22:21:27.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024."}],"balance_after":12000,"derivative":{"exercise_price":1.35,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001213900-24-026724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390024026724/ownership.xml","form_type":"4"}},{"id":1559294,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53062,"kind":"person","name":"Claiborne Cary J","position":1,"cik":"0001370930","reported_name":"Claiborne Cary J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T22:06:59.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024."}],"balance_after":60000,"derivative":{"exercise_price":1.35,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001213900-24-026712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370930/000121390024026712/ownership.xml","form_type":"4"}},{"id":1559270,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53055,"kind":"person","name":"Anderson J. Kermit","position":1,"cik":"0001717983","reported_name":"Anderson J. Kermit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T22:06:33.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024."}],"balance_after":12000,"derivative":{"exercise_price":1.35,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001213900-24-026711","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390024026711/ownership.xml","form_type":"4"}},{"id":1559269,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T22:06:13.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024."}],"balance_after":12000,"derivative":{"exercise_price":1.35,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001213900-24-026708","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390024026708/ownership.xml","form_type":"4"}},{"id":1559544,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53084,"kind":"person","name":"Goodman Tony","position":1,"cik":"0001717971","reported_name":"Goodman Tony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T22:05:45.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024."}],"balance_after":42000,"derivative":{"exercise_price":1.35,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001213900-24-026706","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1717971/000121390024026706/ownership.xml","form_type":"4"}},{"id":1559543,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":92615,"kind":"person","name":"Truluck Joseph","position":1,"cik":"0001718091","reported_name":"Truluck Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T18:07:38.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024."}],"balance_after":25000,"derivative":{"exercise_price":1.35,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001213900-24-026714","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718091/000121390024026714/ownership.xml","form_type":"4"}},{"id":1766686,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-03T12:54:38.000Z","date":"2023-09-29","kind":"purchase","planned":false,"acquired":true,"shares":700,"price":2.74,"value":1918.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.72 through $2.78, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":700,"source":{"system":"sec-edgar","filing":"0001013762-23-000757","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000101376223000757/ownership.xml","form_type":"4"}},{"id":1870040,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":112814,"kind":"person","name":"Johnson Bankole A.","position":1,"cik":"0001718158","reported_name":"Johnson Bankole A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-06-02T07:52:35.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":40000,"derivative":{"exercise_price":0.3025,"exercise_date":"2023-05-23","expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-23-045385","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718158/000121390023045385/ownership.xml","form_type":"4"}},{"id":1877723,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T20:45:28.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."}],"balance_after":50000,"derivative":{"exercise_price":0.3025,"exercise_date":"2023-05-23","expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-23-043125","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023043125/ownership.xml","form_type":"4"}},{"id":1877721,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":78988,"kind":"person","name":"Newman James W. Jr.","position":1,"cik":"0001718364","reported_name":"Newman James W. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T20:43:30.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."}],"balance_after":50000,"derivative":{"exercise_price":0.3025,"exercise_date":"2023-05-23","expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-23-043121","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023043121/ownership.xml","form_type":"4"}},{"id":1878193,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53084,"kind":"person","name":"Goodman Tony","position":1,"cik":"0001717971","reported_name":"Goodman Tony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T20:41:22.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."}],"balance_after":50000,"derivative":{"exercise_price":0.3025,"exercise_date":"2023-05-23","expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-23-043117","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1717971/000121390023043117/ownership.xml","form_type":"4"}},{"id":1877722,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53053,"kind":"person","name":"Gilliland Robertson H.","position":1,"cik":"0001718351","reported_name":"Gilliland Robertson H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T20:38:50.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."}],"balance_after":50000,"derivative":{"exercise_price":0.3025,"exercise_date":"2023-05-23","expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-23-043114","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023043114/ownership.xml","form_type":"4"}},{"id":1877752,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53062,"kind":"person","name":"Claiborne Cary J","position":1,"cik":"0001370930","reported_name":"Claiborne Cary J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T20:36:03.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."}],"balance_after":300000,"derivative":{"exercise_price":0.3025,"exercise_date":"2023-05-23","expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001213900-23-043111","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370930/000121390023043111/ownership.xml","form_type":"4"}},{"id":1877751,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53062,"kind":"person","name":"Claiborne Cary J","position":1,"cik":"0001370930","reported_name":"Claiborne Cary J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-25T20:36:03.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":420000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1520000,"source":{"system":"sec-edgar","filing":"0001213900-23-043111","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370930/000121390023043111/ownership.xml","form_type":"4"}},{"id":1877720,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53055,"kind":"person","name":"Anderson J. Kermit","position":1,"cik":"0001717983","reported_name":"Anderson J. Kermit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T20:34:24.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."}],"balance_after":50000,"derivative":{"exercise_price":0.3025,"exercise_date":"2023-05-23","expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-23-043109","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023043109/ownership.xml","form_type":"4"}},{"id":1878190,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":92615,"kind":"person","name":"Truluck Joseph","position":1,"cik":"0001718091","reported_name":"Truluck Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T16:50:18.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."}],"balance_after":125000,"derivative":{"exercise_price":0.3025,"exercise_date":"2023-05-23","expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001213900-23-043133","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718091/000121390023043133/ownership.xml","form_type":"4"}},{"id":1878189,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":92615,"kind":"person","name":"Truluck Joseph","position":1,"cik":"0001718091","reported_name":"Truluck Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-25T16:50:18.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":157500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":265139,"source":{"system":"sec-edgar","filing":"0001213900-23-043133","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718091/000121390023043133/ownership.xml","form_type":"4"}},{"id":1878192,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":113130,"kind":"person","name":"Stilley William B. III","position":1,"cik":"0001718069","reported_name":"Stilley William B. III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T16:47:59.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023."}],"balance_after":50000,"derivative":{"exercise_price":0.3025,"exercise_date":"2023-05-23","expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-23-043129","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718069/000121390023043129/ownership.xml","form_type":"4"}},{"id":1878191,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":113130,"kind":"person","name":"Stilley William B. III","position":1,"cik":"0001718069","reported_name":"Stilley William B. III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-25T16:47:59.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":240800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1261779,"source":{"system":"sec-edgar","filing":"0001213900-23-043129","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718069/000121390023043129/ownership.xml","form_type":"4"}},{"id":2072707,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":113130,"kind":"person","name":"Stilley William B. III","position":1,"cik":"0001718069","reported_name":"Stilley William B. III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-03T06:02:37.000Z","date":"2022-12-30","kind":"disposition_to_issuer","acquired":false,"shares":166667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the cancellation of 166,667 previously outstanding shares of restricted common stock of Adial Pharmaceuticals, Inc. originally issued on February 23, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents the cancellation of 166,667 previously outstanding shares of restricted common stock of Adial Pharmaceuticals, Inc. originally issued on February 23, 2022."}],"balance_after":1020979,"source":{"system":"sec-edgar","filing":"0001213900-23-000003","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718069/000121390023000003/ownership.xml","form_type":"4"}},{"id":2153907,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53062,"kind":"person","name":"Claiborne Cary J","position":1,"cik":"0001370930","reported_name":"Claiborne Cary J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-09-20T23:11:07.000Z","date":"2022-09-20","kind":"grant","acquired":true,"shares":75000,"price":0.4202,"value":31515.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.4079 through $0.4230, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1100000,"source":{"system":"sec-edgar","filing":"0001213900-22-057513","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370930/000121390022057513/ownership.xml","form_type":"4"}},{"id":2153906,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53062,"kind":"person","name":"Claiborne Cary J","position":1,"cik":"0001370930","reported_name":"Claiborne Cary J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-09-20T23:11:07.000Z","date":"2022-09-19","kind":"grant","acquired":true,"shares":25000,"price":0.4294,"value":10735.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.4196 through $0.4573, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1025000,"source":{"system":"sec-edgar","filing":"0001213900-22-057513","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370930/000121390022057513/ownership.xml","form_type":"4"}},{"id":2176143,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":113130,"kind":"person","name":"Stilley William B. III","position":1,"cik":"0001718069","reported_name":"Stilley William B. III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-08-23T19:14:33.000Z","date":"2022-08-22","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options to purchase 100,000 shares of the Company's common stock, vesting 50% after Purnovate, Inc. has held a pre-IND meeting with the FDA and the balance when the IND is granted."}],"balance_after":100000,"derivative":{"exercise_price":0.555,"exercise_date":"2022-09-01","expiration_date":"2032-08-21","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-22-050596","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718069/000121390022050596/ownership.xml","form_type":"4"}},{"id":2176764,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53062,"kind":"person","name":"Claiborne Cary J","position":1,"cik":"0001370930","reported_name":"Claiborne Cary J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-08-22T20:42:53.000Z","date":"2022-08-18","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are Restricted Stock Units that vest monthly pro rata over the next 36 months."}],"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001213900-22-050082","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370930/000121390022050082/ownership.xml","form_type":"4"}},{"id":2220198,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53084,"kind":"person","name":"Goodman Tony","position":1,"cik":"0001717971","reported_name":"Goodman Tony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-28T22:02:41.000Z","date":"2022-06-27","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."}],"balance_after":25000,"derivative":{"exercise_price":1.23,"exercise_date":"2022-07-27","expiration_date":"2032-06-26","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001213900-22-035649","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1717971/000121390022035649/ownership.xml","form_type":"4"}},{"id":2372190,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53084,"kind":"person","name":"Goodman Tony","position":1,"cik":"0001717971","reported_name":"Goodman Tony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-02-25T20:05:22.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."}],"balance_after":40000,"derivative":{"exercise_price":2,"exercise_date":"2022-03-23","expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-22-009440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1717971/000121390022009440/ownership.xml","form_type":"4"}},{"id":2371507,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-02-25T19:59:15.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."}],"balance_after":40000,"derivative":{"exercise_price":2,"exercise_date":"2022-03-23","expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-22-009430","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390022009430/ownership.xml","form_type":"4"}},{"id":2371506,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":78988,"kind":"person","name":"Newman James W. Jr.","position":1,"cik":"0001718364","reported_name":"Newman James W. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-02-25T19:57:59.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."}],"balance_after":40000,"derivative":{"exercise_price":2,"exercise_date":"2022-03-23","expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-22-009425","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390022009425/ownership.xml","form_type":"4"}},{"id":2371504,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53053,"kind":"person","name":"Gilliland Robertson H.","position":1,"cik":"0001718351","reported_name":"Gilliland Robertson H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-02-25T19:55:52.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."}],"balance_after":40000,"derivative":{"exercise_price":2,"exercise_date":"2022-03-23","expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-22-009422","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390022009422/ownership.xml","form_type":"4"}},{"id":2371533,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53062,"kind":"person","name":"Claiborne Cary J","position":1,"cik":"0001370930","reported_name":"Claiborne Cary J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option","published_at":"2022-02-25T19:54:37.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."}],"balance_after":6667,"derivative":{"exercise_price":2,"exercise_date":"2022-03-23","expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0001213900-22-009419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370930/000121390022009419/ownership.xml","form_type":"4"}},{"id":2371505,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53055,"kind":"person","name":"Anderson J. Kermit","position":1,"cik":"0001717983","reported_name":"Anderson J. Kermit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-02-25T19:53:09.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."}],"balance_after":40000,"derivative":{"exercise_price":2,"exercise_date":"2022-03-23","expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-22-009417","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390022009417/ownership.xml","form_type":"4"}},{"id":2372187,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":112814,"kind":"person","name":"Johnson Bankole A.","position":1,"cik":"0001718158","reported_name":"Johnson Bankole A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option","published_at":"2022-02-25T15:18:31.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."}],"balance_after":35000,"derivative":{"exercise_price":2,"exercise_date":"2022-03-23","expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-22-009451","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718158/000121390022009451/ownership.xml","form_type":"4"}},{"id":2372188,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":92615,"kind":"person","name":"Truluck Joseph","position":1,"cik":"0001718091","reported_name":"Truluck Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option","published_at":"2022-02-25T15:02:28.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022."}],"balance_after":100000,"derivative":{"exercise_price":2,"exercise_date":"2022-03-23","expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-22-009437","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718091/000121390022009437/ownership.xml","form_type":"4"}},{"id":2372189,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":113130,"kind":"person","name":"Stilley William B. III","position":1,"cik":"0001718069","reported_name":"Stilley William B. III","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-25T15:00:40.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted shares of Adial Pharmaceuticals, Inc. (the \"Company\") common stock, par value $0.001 per share (the \"Common Stock\"), vest as to 166,667 shares monthly on a pro rata basis over 24 months commencing March 23, 2022 and vest as to 83,333 shares on the three year anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The restricted shares of Adial Pharmaceuticals, Inc. (the \"Company\") common stock, par value $0.001 per share (the \"Common Stock\"), vest as to 166,667 shares monthly on a pro rata basis over 24 months commencing March 23, 2022 and vest as to 83,333 shares on the three year anniversary of the grant date."}],"balance_after":1187646,"source":{"system":"sec-edgar","filing":"0001213900-22-009432","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718069/000121390022009432/ownership.xml","form_type":"4"}},{"id":2453743,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":78988,"kind":"person","name":"Newman James W. Jr.","position":1,"cik":"0001718364","reported_name":"Newman James W. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-03T15:39:28.000Z","date":"2021-12-30","kind":"purchase","acquired":true,"shares":10000,"price":2.71,"value":27100.0,"ownership":{"direct":false,"nature":"Roth IRA FBO James W Newman, Jr."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in column 4 is a weighted average price. The shares were sold in multiple transaction at prices ranging from $2.655 to $2.72, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Courtney Newman is the daughter of James W. Newman, Jr."}],"balance_after":34644,"source":{"system":"sec-edgar","filing":"0001213900-22-000067","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390022000067/ownership.xml","form_type":"4"}},{"id":2453742,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":78988,"kind":"person","name":"Newman James W. Jr.","position":1,"cik":"0001718364","reported_name":"Newman James W. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-03T15:39:28.000Z","date":"2021-12-30","kind":"purchase","acquired":true,"shares":5000,"price":2.72,"value":13600.0,"ownership":{"direct":false,"nature":"Ivy Cottage Group, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"James W. Newman is the general partner of Ivy Cottage Group, LLC."}],"balance_after":50221,"source":{"system":"sec-edgar","filing":"0001213900-22-000067","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390022000067/ownership.xml","form_type":"4"}},{"id":2453741,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":78988,"kind":"person","name":"Newman James W. Jr.","position":1,"cik":"0001718364","reported_name":"Newman James W. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-03T15:39:28.000Z","date":"2021-12-30","kind":"purchase","acquired":true,"shares":10000,"price":2.66,"value":26600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The shares were sold in multiple transaction at prices ranging from $2.628 to $2.68, inclusive. The reporting person undertakes to provide Adial Pharmaceuticals, Inc., any security holder of Adial Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (6) of this Form 4."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001213900-22-000067","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390022000067/ownership.xml","form_type":"4"}},{"id":2459337,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to purchase common stock","published_at":"2021-12-23T22:04:52.000Z","date":"2021-12-23","kind":"gift","acquired":false,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Mr. Schuyler gifted the securities to a newly formed charitable trust (the \"Trust\"), the trustee of which is his adult son who controls the Trust."}],"balance_after":0,"derivative":{"exercise_price":6.25,"exercise_date":"2018-07-31","expiration_date":"2023-07-31","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001213900-21-067352","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021067352/ownership.xml","form_type":"4"}},{"id":2459336,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-23T22:04:52.000Z","date":"2021-12-23","kind":"gift","acquired":false,"shares":312990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Mr. Schuyler gifted the securities to a newly formed charitable trust (the \"Trust\"), the trustee of which is his adult son who controls the Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-21-067352","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021067352/ownership.xml","form_type":"4"}},{"id":2480264,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53062,"kind":"person","name":"Claiborne Cary J","position":1,"cik":"0001370930","reported_name":"Claiborne Cary J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock options","published_at":"2021-12-09T02:23:51.000Z","date":"2021-12-07","kind":"grant","acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."}],"balance_after":130000,"derivative":{"exercise_price":2.77,"exercise_date":"2021-12-07","expiration_date":"2031-12-08","underlying":"Common stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001213900-21-064281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370930/000121390021064281/ownership.xml","form_type":"4"}},{"id":2490661,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":113130,"kind":"person","name":"Stilley William B. III","position":1,"cik":"0001718069","reported_name":"Stilley William B. III","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-01T09:25:37.000Z","date":"2021-11-30","kind":"purchase","acquired":true,"shares":10600,"price":2.7527,"value":29178.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price. These 10,600 shares of common stock were purchased in multiple transactions at prices ranging from $2.5999 to $2.83, inclusive. The reporting person undertakes to provide to Adial Pharmaceuticals, Inc., any security holder of Adial Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These 10,600 shares of common stock were purchased in multiple transactions at prices ranging from $2.5999 to $2.83, inclusive. The reporting person undertakes to provide to Adial Pharmaceuticals, Inc., any security holder of Adial Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4"}],"balance_after":937646,"source":{"system":"sec-edgar","filing":"0001213900-21-062729","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718069/000121390021062729/ownership.xml","form_type":"4"}},{"id":2490660,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":113130,"kind":"person","name":"Stilley William B. III","position":1,"cik":"0001718069","reported_name":"Stilley William B. III","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-01T09:25:37.000Z","date":"2021-11-29","kind":"purchase","acquired":true,"shares":10000,"price":2.5892,"value":25892.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The price reported in Column 4 is a weighted average price. These 10,000 shares of common stock were purchased in multiple transactions at prices ranging from $2.54 to $2.60, inclusive. The reporting person undertakes to provide to Adial Pharmaceuticals, Inc., any security holder of Adial Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These 10,000 shares of common stock were purchased in multiple transactions at prices ranging from $2.54 to $2.60, inclusive. The reporting person undertakes to provide to Adial Pharmaceuticals, Inc., any security holder of Adial Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4"}],"balance_after":927046,"source":{"system":"sec-edgar","filing":"0001213900-21-062729","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718069/000121390021062729/ownership.xml","form_type":"4"}},{"id":2491853,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":78988,"kind":"person","name":"Newman James W. Jr.","position":1,"cik":"0001718364","reported_name":"Newman James W. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-30T14:25:43.000Z","date":"2021-11-26","kind":"purchase","acquired":true,"shares":10000,"price":2.85,"value":28500.0,"ownership":{"direct":false,"nature":"Rountop Limited Partnership, LLP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"James W. Newman, Jr. is the general partner of Roundtop Limited Partnership, LLP."}],"balance_after":34475,"source":{"system":"sec-edgar","filing":"0001213900-21-062465","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021062465/ownership.xml","form_type":"4"}},{"id":2525829,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53062,"kind":"person","name":"Claiborne Cary J","position":1,"cik":"0001370930","reported_name":"Claiborne Cary J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-11-03T20:35:49.000Z","date":"2021-11-02","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."}],"balance_after":60000,"derivative":{"exercise_price":3.15,"exercise_date":"2021-11-02","expiration_date":"2031-11-01","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001213900-21-056466","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370930/000121390021056466/ownership.xml","form_type":"4"}},{"id":2547222,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":112814,"kind":"person","name":"Johnson Bankole A.","position":1,"cik":"0001718158","reported_name":"Johnson Bankole A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Warrant","published_at":"2021-10-06T17:22:19.000Z","date":"2021-10-04","kind":"other","acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On October 4, 2021, Dr. Johnson sold warrants to purchase 150,000 shares of the issuer's common stock pursuant to the SPA, for an aggregate purchase price of $1,500. The warrants provide for an exercise price of $6.25 per share and expire five years after issuance."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On October 4, 2021, Dr. Johnson sold warrants to purchase 150,000 shares of the issuer's common stock pursuant to the SPA, for an aggregate purchase price of $1,500. The warrants provide for an exercise price of $6.25 per share and expire five years after issuance."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On October 4, 2021, Dr. Johnson sold warrants to purchase 150,000 shares of the issuer's common stock pursuant to the SPA, for an aggregate purchase price of $1,500. The warrants provide for an exercise price of $6.25 per share and expire five years after issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On October 4, 2021, Dr. Johnson sold warrants to purchase 150,000 shares of the issuer's common stock pursuant to the SPA, for an aggregate purchase price of $1,500. The warrants provide for an exercise price of $6.25 per share and expire five years after issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On October 4, 2021, Dr. Johnson sold warrants to purchase 150,000 shares of the issuer's common stock pursuant to the SPA, for an aggregate purchase price of $1,500. The warrants provide for an exercise price of $6.25 per share and expire five years after issuance."}],"balance_after":39714,"derivative":{"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001213900-21-051646","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718158/000121390021051646/ownership.xml","form_type":"4"}},{"id":2547221,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":112814,"kind":"person","name":"Johnson Bankole A.","position":1,"cik":"0001718158","reported_name":"Johnson Bankole A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-06T17:22:19.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":200000,"ownership":{"direct":false,"nature":"By En Fideicomiso De Mi Vida 11/23/2010 (Trust)"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"En Fideicomiso De Mi Vida 11/23/2010 (the \"Trust\") sold 200,000 shares of the issuer's common stock pursuant to a Stock Purchase Agreement dated as of October 1, 2021 (the \"SPA\"), for an aggregate purchase price of $200,000."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"En Fideicomiso De Mi Vida 11/23/2010 (the \"Trust\") sold 200,000 shares of the issuer's common stock pursuant to a Stock Purchase Agreement dated as of October 1, 2021 (the \"SPA\"), for an aggregate purchase price of $200,000."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Johnson is the trustee of the Trust."}],"balance_after":148246,"source":{"system":"sec-edgar","filing":"0001213900-21-051646","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718158/000121390021051646/ownership.xml","form_type":"4"}},{"id":2752988,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":112814,"kind":"person","name":"Johnson Bankole A.","position":1,"cik":"0001718158","reported_name":"Johnson Bankole A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-08T21:47:32.000Z","date":"2021-04-06","kind":"sale","acquired":false,"shares":150000,"price":2.5,"value":375000.0,"ownership":{"direct":false,"nature":"En Fideicomiso De Mi Vida 11/23/2010 (Trust)"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person sold 150,000 shares of the issuer's common stock pursuant to a Stock Purchase Agreement dated as of April 6, 2021 for an aggregate purchase price of $375,000."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Dr. Johnson is the trustee of each of these trusts."}],"balance_after":548336,"source":{"system":"sec-edgar","filing":"0001213900-21-020918","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1718158/000121390021020918/ownership.xml","form_type":"4"}},{"id":2868634,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-02-10T22:56:41.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."}],"balance_after":40000,"derivative":{"exercise_price":3.11,"exercise_date":"2021-03-08","expiration_date":"2031-02-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-21-008168","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021008168/ownership.xml","form_type":"4"}},{"id":2868633,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":78988,"kind":"person","name":"Newman James W. Jr.","position":1,"cik":"0001718364","reported_name":"Newman James W. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-02-10T22:54:10.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."}],"balance_after":40000,"derivative":{"exercise_price":3.11,"exercise_date":"2021-03-08","expiration_date":"2031-02-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-21-008165","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021008165/ownership.xml","form_type":"4"}},{"id":2869305,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53084,"kind":"person","name":"Goodman Tony","position":1,"cik":"0001717971","reported_name":"Goodman Tony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-02-10T22:51:16.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."}],"balance_after":40000,"derivative":{"exercise_price":3.11,"exercise_date":"2021-03-08","expiration_date":"2031-02-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-21-008162","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1717971/000121390021008162/ownership.xml","form_type":"4"}},{"id":2868632,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53053,"kind":"person","name":"Gilliland Robertson H.","position":1,"cik":"0001718351","reported_name":"Gilliland Robertson H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-02-10T22:48:48.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."}],"balance_after":40000,"derivative":{"exercise_price":3.11,"exercise_date":"2021-03-08","expiration_date":"2031-02-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-21-008158","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021008158/ownership.xml","form_type":"4"}},{"id":2868631,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53055,"kind":"person","name":"Anderson J. Kermit","position":1,"cik":"0001717983","reported_name":"Anderson J. Kermit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-02-10T22:46:55.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."}],"balance_after":40000,"derivative":{"exercise_price":3.11,"exercise_date":"2021-03-08","expiration_date":"2031-02-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-21-008154","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021008154/ownership.xml","form_type":"4"}},{"id":2869303,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":92615,"kind":"person","name":"Truluck Joseph","position":1,"cik":"0001718091","reported_name":"Truluck Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option","published_at":"2021-02-10T18:12:32.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."}],"balance_after":125000,"derivative":{"exercise_price":3.11,"exercise_date":"2021-03-08","expiration_date":"2031-02-07","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001213900-21-008175","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718091/000121390021008175/ownership.xml","form_type":"4"}},{"id":2869304,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":113130,"kind":"person","name":"Stilley William B. III","position":1,"cik":"0001718069","reported_name":"Stilley William B. III","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option","published_at":"2021-02-10T18:10:24.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests pro rata on a monthly basis over 36 months."}],"balance_after":250000,"derivative":{"exercise_price":3.11,"exercise_date":"2021-03-08","expiration_date":"2031-02-07","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001213900-21-008172","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718069/000121390021008172/ownership.xml","form_type":"4"}},{"id":2891890,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":78988,"kind":"person","name":"Newman James W. Jr.","position":1,"cik":"0001718364","reported_name":"Newman James W. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-29T00:44:25.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":2544,"ownership":{"direct":false,"nature":"Virga Ventures, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person acquired an aggregate of 3,731 shares of issuer common stock in exchange for an aggregate 0.53% interest in Purnovate, LLC (\"Purnovate\") pursuant to Purnovate's merger into a wholly owned subsidiary of the issuer, as contemplated by that certain Equity Purchase Agreement, dated December 7, 2020, as amended. The shares issued to the reporting person in the merger are currently being held in escrow and 70% of the shares are subject to forfeiture during a one year period following the merger to satisfy claims arising as a result of Purnovate's breach of any of its representations and warranties or covenants in the purchase agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"James W. Newman is the sole member of Virga Ventures, LLC."}],"balance_after":152963,"source":{"system":"sec-edgar","filing":"0001213900-21-005041","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021005041/ownership.xml","form_type":"4"}},{"id":2891889,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":78988,"kind":"person","name":"Newman James W. Jr.","position":1,"cik":"0001718364","reported_name":"Newman James W. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-29T00:44:25.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":1187,"ownership":{"direct":false,"nature":"Roundtop Limited Partnership, LLP"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person acquired an aggregate of 3,731 shares of issuer common stock in exchange for an aggregate 0.53% interest in Purnovate, LLC (\"Purnovate\") pursuant to Purnovate's merger into a wholly owned subsidiary of the issuer, as contemplated by that certain Equity Purchase Agreement, dated December 7, 2020, as amended. The shares issued to the reporting person in the merger are currently being held in escrow and 70% of the shares are subject to forfeiture during a one year period following the merger to satisfy claims arising as a result of Purnovate's breach of any of its representations and warranties or covenants in the purchase agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person acquired an aggregate of 3,731 shares of issuer common stock in exchange for an aggregate 0.53% interest in Purnovate, LLC (\"Purnovate\") pursuant to Purnovate's merger into a wholly owned subsidiary of the issuer, as contemplated by that certain Equity Purchase Agreement, dated December 7, 2020, as amended. The shares issued to the reporting person in the merger are currently being held in escrow and 70% of the shares are subject to forfeiture during a one year period following the merger to satisfy claims arising as a result of Purnovate's breach of any of its representations and warranties or covenants in the purchase agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"James W. Newman is the general partner of Roundtop Limited Partnership, LLP."}],"balance_after":14475,"source":{"system":"sec-edgar","filing":"0001213900-21-005041","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021005041/ownership.xml","form_type":"4"}},{"id":2892192,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":113130,"kind":"person","name":"Stilley William B. III","position":1,"cik":"0001718069","reported_name":"Stilley William B. III","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-28T19:45:34.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":201109,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person acquired 201,109 shares of issuer common stock in exchange for an 28.7% interest in Purnovate, LLC (\"Purnovate\") pursuant to Purnovate's merger into a wholly owned subsidiary of the issuer, as contemplated by that certain Equity Purchase Agreement, dated December 7, 2020, as amended. The shares issued to the reporting person in the merger are currently being held in escrow and are subject to forfeiture during the two-year period following the merger to satisfy claims arising as a result of Purnovate's breach of any of its representations and warranties or covenants in the purchase agreement."}],"balance_after":917046,"source":{"system":"sec-edgar","filing":"0001213900-21-005043","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718069/000121390021005043/ownership.xml","form_type":"4"}},{"id":2965788,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to purchase common stock","published_at":"2020-11-25T21:51:34.000Z","date":"2018-11-12","kind":"other","acquired":true,"shares":192600,"ownership":{"direct":false,"nature":"Owned by MVA 151 Investors LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect that on November 12, 2018, MVA 151 Investors LLC exchanged a warrant to purchase 192,600 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 192,600 shares of common stock. Mr. Schuyler has control over MVA 151 Investors LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect that on November 12, 2018, MVA 151 Investors LLC exchanged a warrant to purchase 192,600 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 192,600 shares of common stock. Mr. Schuyler has control over MVA 151 Investors LLC."}],"balance_after":192600,"derivative":{"exercise_price":6.25,"exercise_date":"2018-11-12","expiration_date":"2023-07-31","underlying":"Common Stock","underlying_shares":192600},"source":{"system":"sec-edgar","filing":"0001213900-20-039340","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390020039340/ownership.xml","form_type":"4/A","original_submission_date":"2018-11-13"}},{"id":2965787,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to purchase common stock","published_at":"2020-11-25T21:51:34.000Z","date":"2018-11-12","kind":"other","acquired":true,"shares":192600,"ownership":{"direct":false,"nature":"Owned by MVA 151 Investors LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect that on November 12, 2018, MVA 151 Investors LLC exchanged a warrant to purchase 192,600 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 192,600 shares of common stock. Mr. Schuyler has control over MVA 151 Investors LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect that on November 12, 2018, MVA 151 Investors LLC exchanged a warrant to purchase 192,600 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 192,600 shares of common stock. Mr. Schuyler has control over MVA 151 Investors LLC."}],"balance_after":192600,"derivative":{"exercise_price":5,"exercise_date":"2018-11-12","expiration_date":"2023-07-31","underlying":"Common Stock","underlying_shares":192600},"source":{"system":"sec-edgar","filing":"0001213900-20-039340","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390020039340/ownership.xml","form_type":"4/A","original_submission_date":"2018-11-13"}},{"id":2965786,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to purchase units","published_at":"2020-11-25T21:51:34.000Z","date":"2018-11-12","kind":"other","acquired":false,"shares":192600,"ownership":{"direct":false,"nature":"Owned by MVA 151 Investors LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect that on November 12, 2018, MVA 151 Investors LLC exchanged a warrant to purchase 192,600 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 192,600 shares of common stock. Mr. Schuyler has control over MVA 151 Investors LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect that on November 12, 2018, MVA 151 Investors LLC exchanged a warrant to purchase 192,600 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 192,600 shares of common stock. Mr. Schuyler has control over MVA 151 Investors LLC."}],"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2018-07-31","expiration_date":"2023-07-31","underlying":"Units","underlying_shares":385200},"source":{"system":"sec-edgar","filing":"0001213900-20-039340","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390020039340/ownership.xml","form_type":"4/A","original_submission_date":"2018-11-13"}},{"id":2965785,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to purchase common stock","published_at":"2020-11-25T21:51:34.000Z","date":"2018-11-12","kind":"other","acquired":true,"shares":89600,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect that on November 12, 2018, Mr. Schuyler exchanged a warrant to purchase 89,600 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 89,600 shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect that on November 12, 2018, Mr. Schuyler exchanged a warrant to purchase 89,600 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 89,600 shares of common stock."}],"balance_after":89600,"derivative":{"exercise_price":6.25,"exercise_date":"2018-11-12","expiration_date":"2023-07-31","underlying":"Common Stock","underlying_shares":89600},"source":{"system":"sec-edgar","filing":"0001213900-20-039340","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390020039340/ownership.xml","form_type":"4/A","original_submission_date":"2018-11-13"}},{"id":2965784,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to purchase common stock","published_at":"2020-11-25T21:51:34.000Z","date":"2018-11-12","kind":"other","acquired":true,"shares":89600,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect that on November 12, 2018, Mr. Schuyler exchanged a warrant to purchase 89,600 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 89,600 shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect that on November 12, 2018, Mr. Schuyler exchanged a warrant to purchase 89,600 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 89,600 shares of common stock."}],"balance_after":89600,"derivative":{"exercise_price":5,"exercise_date":"2018-11-12","expiration_date":"2023-07-31","underlying":"Common Stock","underlying_shares":89600},"source":{"system":"sec-edgar","filing":"0001213900-20-039340","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390020039340/ownership.xml","form_type":"4/A","original_submission_date":"2018-11-13"}},{"id":2965783,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to purchase units","published_at":"2020-11-25T21:51:34.000Z","date":"2018-11-12","kind":"other","acquired":false,"shares":89600,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect that on November 12, 2018, Mr. Schuyler exchanged a warrant to purchase 89,600 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 89,600 shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect that on November 12, 2018, Mr. Schuyler exchanged a warrant to purchase 89,600 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 89,600 shares of common stock."}],"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2018-07-31","expiration_date":"2023-07-31","underlying":"Units","underlying_shares":179200},"source":{"system":"sec-edgar","filing":"0001213900-20-039340","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390020039340/ownership.xml","form_type":"4/A","original_submission_date":"2018-11-13"}},{"id":2965782,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to purchase units","published_at":"2020-11-25T21:50:03.000Z","date":"2018-07-31","kind":"other","acquired":true,"shares":192600,"ownership":{"direct":false,"nature":"Owned by MVA 151 Investors, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 units was received by MVA 151 Investors LLC upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 385,200 shares."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 units was received by MVA 151 Investors LLC upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 385,200 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Schuyler has control over MVA 151 Investors, LLC."}],"balance_after":192600,"derivative":{"exercise_price":5,"exercise_date":"2018-07-31","expiration_date":"2023-07-31","underlying":"Units","underlying_shares":385200},"source":{"system":"sec-edgar","filing":"0001213900-20-039338","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390020039338/ownership.xml","form_type":"4/A","original_submission_date":"2018-08-02"}},{"id":2965781,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to purchase units","published_at":"2020-11-25T21:50:03.000Z","date":"2018-07-31","kind":"other","acquired":true,"shares":89600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect the purchase 89,600 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 179,200 shares."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect the purchase 89,600 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 179,200 shares."}],"balance_after":89600,"derivative":{"exercise_price":5,"exercise_date":"2018-07-31","expiration_date":"2023-07-31","underlying":"Units","underlying_shares":179200},"source":{"system":"sec-edgar","filing":"0001213900-20-039338","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390020039338/ownership.xml","form_type":"4/A","original_submission_date":"2018-08-02"}},{"id":2965780,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to purchase common stock","published_at":"2020-11-25T21:50:03.000Z","date":"2018-07-31","kind":"other","acquired":true,"shares":192600,"ownership":{"direct":false,"nature":"Owned by MVA 151 Investors, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 shares of common stock and warrants to purchase 192,600 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 shares of common stock and warrants to purchase 192,600 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Schuyler has control over MVA 151 Investors, LLC."}],"balance_after":192600,"derivative":{"exercise_price":6.25,"exercise_date":"2018-07-31","expiration_date":"2023-07-31","underlying":"Common Stock","underlying_shares":192200},"source":{"system":"sec-edgar","filing":"0001213900-20-039338","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390020039338/ownership.xml","form_type":"4/A","original_submission_date":"2018-08-02"}},{"id":2965779,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to purchase common stock","published_at":"2020-11-25T21:50:03.000Z","date":"2018-07-31","kind":"purchase","acquired":true,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the \"Units\") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the \"Units\") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering."}],"balance_after":90000,"derivative":{"exercise_price":6.25,"exercise_date":"2018-07-31","expiration_date":"2023-07-31","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001213900-20-039338","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390020039338/ownership.xml","form_type":"4/A","original_submission_date":"2018-08-02"}},{"id":2965778,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to purchase common stock","published_at":"2020-11-25T21:50:03.000Z","date":"2018-07-31","kind":"other","acquired":true,"shares":89600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 89,600 shares of common stock and warrants to purchase 89,600 shares of common stock that were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 89,600 shares of common stock and warrants to purchase 89,600 shares of common stock that were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018."}],"balance_after":89600,"derivative":{"exercise_price":6.25,"exercise_date":"2018-07-31","expiration_date":"2023-07-31","underlying":"Common Stock","underlying_shares":89600},"source":{"system":"sec-edgar","filing":"0001213900-20-039338","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390020039338/ownership.xml","form_type":"4/A","original_submission_date":"2018-08-02"}},{"id":2965777,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-25T21:50:03.000Z","date":"2018-07-31","kind":"other","acquired":true,"shares":144200,"ownership":{"direct":false,"nature":"Owned by MVA 151 Investors, LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 shares of common stock and warrants to purchase 192,600 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 shares of common stock and warrants to purchase 192,600 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the \"Units\") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering."}],"balance_after":144200,"source":{"system":"sec-edgar","filing":"0001213900-20-039338","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390020039338/ownership.xml","form_type":"4/A","original_submission_date":"2018-08-02"}},{"id":2965776,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-25T21:50:03.000Z","date":"2018-07-31","kind":"purchase","acquired":true,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the \"Units\") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the \"Units\") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering."}],"balance_after":312990,"source":{"system":"sec-edgar","filing":"0001213900-20-039338","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390020039338/ownership.xml","form_type":"4/A","original_submission_date":"2018-08-02"}},{"id":2965775,"issuer":{"id":7742,"kind":"organization","name":"ADIAL PHARMACEUTICALS, INC.","symbol":"ADIL"},"owners":[{"id":53054,"kind":"person","name":"Schuyler Kevin","position":1,"cik":"0001718094","reported_name":"Schuyler Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-25T21:50:03.000Z","date":"2018-07-31","kind":"other","acquired":true,"shares":89600,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 89,600 shares of common stock and warrants to purchase 89,600 shares of common stock that were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 89,600 shares of common stock and warrants to purchase 89,600 shares of common stock that were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018."}],"balance_after":222990,"source":{"system":"sec-edgar","filing":"0001213900-20-039338","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390020039338/ownership.xml","form_type":"4/A","original_submission_date":"2018-08-02"}}],"next_cursor":"2020-11-25T21:50:03.000000Z,2965775"}